International Journal of Molecular Sciences Article Redefining the Role of ADAM17 in Renal Proximal Tubular Cells and Its Implications in an Obese Mouse Model of Pre-Diabetes Vanesa Palau 1 , Sofia Villanueva 1 , Josué Jarrín 1 , David Benito 1 , Eva Márquez 1 , Eva Rodríguez 1 , María José Soler 2 , Anna Oliveras 1 , Javier Gimeno 3 , Laia Sans 1 , Marta Crespo 1 , Julio Pascual 1,† , Clara Barrios 1, * and Marta Riera 1, * 1 Department of Nephrology, Hospital del Mar-Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain; vpalau@imim.es (V.P.); villanuevas2c@gmail.com (S.V.); JavierJCarriel@outlook.com (J.J.); david.benito.guasch@gmail.com (D.B.); eva.marquez.mosquera@psmar.cat (E.M.); erodriguezg@psmar.cat (E.R.); aoliveras@psmar.cat (A.O.); lsans@psmar.cat (L.S.); mcrespo@psmar.cat (M.C.); julpascual@gmail.com (J.P.) 2 Nephrology Research Group, Vall d’Hebron Research Institute (VHIR), Nephrology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; mjsoler01@gmail.com 3 Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain; JGimenoBeltran@parcdesalutmar.cat * Correspondence: cbarrios@psmar.cat (C.B.); mriera1@imim.es (M.R.); Tel.: +34-65-004-2149 (C.B.); +34-93-316-0626 (M.R.)   † Current address: Department of Nephrology Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. Citation: Palau, V.; Villanueva, S.; Abstract: Acute and chronic kidney lesions induce an increase in A Disintegrin And Metallopro- Jarrín, J.; Benito, D.; Márquez, E.; teinase domain 17 (ADAM17) that cleaves several transmembrane proteins related to inflammatory Rodríguez, E.; Soler, M.J.; Oliveras, and fibrotic pathways. Our group has demonstrated that renal ADAM17 is upregulated in diabetic A.; Gimeno, J.; Sans, L.; et al. mice and its inhibition decreases renal inflammation and fibrosis. The purpose of the present study Redefining the Role of ADAM17 in was to analyze how Adam17 deletion in proximal tubules affects different renal structures in an Renal Proximal Tubular Cells and Its obese mice model. Tubular Adam17 knockout male mice and their controls were fed a high-fat Implications in an Obese Mouse Model of Pre-Diabetes. Int. J. Mol. Sci. diet (HFD) for 22 weeks. Glucose tolerance, urinary albumin-to-creatinine ratio, renal histology, 2021, 22, 13093. https://doi.org/ and pro-inflammatory and pro-fibrotic markers were evaluated. Results showed that wild-type 10.3390/ijms222313093 mice fed an HFD became obese with glucose intolerance and renal histological alterations mim- icking a pre-diabetic condition; consequently, greater glomerular size and mesangial expansion Academic Editor: Giuseppina were observed. Adam17 tubular deletion improved glucose tolerance and protected animals against T. Russo glomerular injury and prevented podocyte loss in HFD mice. In addition, HFD mice showed more glomerular macrophages and collagen accumulation, which was prevented by Adam17 deletion. Received: 29 October 2021 Galectin-3 expression increased in the proximal tubules and glomeruli of HFD mice and ameliorated Accepted: 30 November 2021 with Adam17 deletion. In conclusion, Adam17 in proximal tubules influences glucose tolerance and Published: 3 December 2021 participates in the kidney injury in an obese pre-diabetic murine model. The role of ADAM17 in the tubule impacts on glomerular inflammation and fibrosis. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in Keywords: ADAM17; obesity; pre-diabetes; renal proximal tubular cells published maps and institutional affil- iations. 1. Introduction Copyright: © 2021 by the authors. Obesity has become a worldwide pandemic recognized as a major and independent Licensee MDPI, Basel, Switzerland. risk factor for the development of chronic kidney disease (CKD), and its prevalence will This article is an open access article increase in the next decade [1]. Obesity is characterized by the concurrent existence of distributed under the terms and glucose intolerance, diabetes, dyslipidemia, and cardiovascular disease [2]. In an obese conditions of the Creative Commons state, factors derived from adipocytes induce macrophage activation and infiltration. These Attribution (CC BY) license (https:// activated macrophages secrete a large amount of adipokines, pro-inflammatory cytokines, creativecommons.org/licenses/by/ and chemokines into the circulation, which make obesity a chronic inflammation state that 4.0/). leads to the eventual development of insulin resistance [3,4]. Int. J. Mol. Sci. 2021, 22, 13093. https://doi.org/10.3390/ijms222313093 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, 13093 2 of 15 Some of the deleterious renal consequences of obesity may be mediated by comorbid factors such as diabetes mellitus or hypertension, but also hyperactivation of endocrine activity in the adipose tissue could impact target organs. These include the develop- ment of inflammation, oxidative stress, abnormal lipid metabolism, activation of the renin–angiotensin–aldosterone system, and increased production of insulin and insulin resistance [1,4]. A Disintegrin And Metalloproteinases (ADAMs) are membrane-anchored cell sur- face and secreted proteins [5] that play an important role modulating cell signaling and biological responses by ectodomain shedding of various molecules including cytokines, growth factors, receptors, cell adhesion molecules, and enzymes [5,6]. ADAM17, one of the most studied ADAMs family members, contributes to the development of chronic kidney disease by activating inflammatory and proliferative processes through Tumor Necrosis Factor alpha (TNF-α) and Endothelial Growth Factor Receptor (EGFR) signaling pathways [7]. There is a well-recognized link between TNF-α and obesity, inflammation, and hyperglycemia. In obese and insulin-resistant patients, as well as in animal mod- els, adipose tissue shows an increased expression of TNF-α [8]. Due to the key role of ADAM17 in diverse processes and pathologies, it has been proposed as a target for de- veloping new therapies for the treatment of inflammation and inflammation-associated cancer. Interestingly, blockers of ADAM17 have been considered for clinical trials in several diseases including cancer and type 1 and type 2 diabetes (NCT04630769, NCT02141451, NCT00312780, NCT04557228, NCT01223196). In experimental studies, high-fat diet (HFD) renders obesity, increased systolic blood pressure, and systemic metabolic alterations related to insulin resistance, increased fasting blood glucose, abnormal lipid levels, and renal alterations such as hyperfiltration with increased albuminuria and progression of glomerulopathies [9]. Interestingly, either a genetic reduction of ADAM17 expression or pharmacological inhibition of ADAM17 in HFD-fed mice partially protected from obesity and insulin resistance compared with wild- type mice [10,11], suggesting that ADAM17 is an important mediator in the development of obesity-induced metabolic disorders. In healthy kidneys, ADAM17 is mainly expressed in distal tubules, while it is mostly undetected in proximal tubules, mesangium, and endothelial cells. In contrast, in renal diseases, ADAM17 expression appears de novo in proximal tubules, peritubular capillar- ies, glomerular mesangium, and interstitial inflammatory cells [12]. The specific role of ADAM17 in proximal tubular cells in obese high-fat diet models has not been addressed. For that reason, the present study aims to decipher whether specific Adam17 deletion on renal proximal tubular cells is able to modulate kidney pathophysiology, inflammatory, and fibrotic processes in an induced obese pre-diabetic mice model fed a high-fat diet. 2. Results 2.1. Tubular Adam17 Deletion Modifies Blood Glucose Levels and Renal Function in Obese Mice To investigate the impact of renal proximal tubular Adam17 deletion on kidneys from obese mice, we studied male animals fed an HFD for 22 weeks. As shown in Table 1, the HFD groups were heavier as compared to mice fed a standard diet (SD). HFD mice gained 50 g of body weight at the end of the study and were considered obese. This change was not reflected in kidney weight, where all groups showed similar values. As depicted in Table 1, fasting blood glucose levels were higher in control mice fed an HFD as compared to mice fed an SD, but without exceeding 250 mg/dL. Therefore, HFD mice were considered pre-diabetic, as described before [13]. Interestingly, HFD mice with proximal tubular Adam17 deletion showed similar fasting blood glucose levels as compared to SD mice. To test kidney damage, urine albuminuria was calculated by the albumin-to-creatinine ratio (ACR). As shown in Table 1, all HFD-fed mice had a significant increase in ACR. cant increase in ACR. Table 1. Fasting blood glucose, body weight, kidney weight, and albumin-to-creatinine ratio were measured after 22 weeks of follow-up. Values are expressed as mean ± SD. Abbreviations: SD, standard diet; HFD, high-fat diet; Adam17WT, wild-type; Int. J. Mol. Adam17KO, Sci. 2021, 22, 13093 knockout. * p < 0.05 HFD vs. SD. 3 of 15 Fasting Blood Glucose Body Weight Kidney Weight ACR (mg/dL) (g) (g) (μg Alb/mg Crea) Adam17WT—SD 191.91 ±body Table 1. Fasting blood glucose, 13.66weight, kidney 34.01 ± 2.70and albumin-to-creatinine weight, 0.41 ± 0.07 ratio were measured 21.80 ± after 4.83 22 Adam17WT—HFD 236.63 weeks of follow-up. Values ± 28.38 * as mean ±53.18 are expressed ± 1.83 * SD. Abbreviations: 0.39 ± diet; SD, standard 0.04 HFD, high-fat48.77 ± 21.49 * diet; Adam17WT, Adam17KO—SD 199.13 ± *16.80 wild-type; Adam17KO, knockout. 37.22 ± 4.12 p < 0.05 HFD vs. SD. 0.39 ± 0.05 26.78 ± 11.71 Adam17KO—HFD 218.63 ± 38.53 54.30 ± 8.52 * 0.42 ± 0.08 62.31 ± 27.68 * Fasting Blood Glucose Body Weight Kidney Weight ACR (mg/dL) (g) (g) (µg Alb/mg Crea) 2.2. Glucose Homeostasis Is Influenced by Tubular Adam17 Deletion Adam17WT—SD 191.91 ± 13.66 34.01 ± 2.70 0.41 ± 0.07 21.80 ± 4.83 Adam17WT—HFD 236.63 Glucose ± 28.38 * tolerance was 53.18measured, ± 1.83 * in all groups0.39at ± 32 0.04weeks of age,48.77 by performing ± 21.49 * an Adam17KO—SD intraperitoneal 199.13 ± 16.80 glucose tolerance test (IPGTT) to evaluate 37.22 ± 4.12 the impact of HFD 0.39 ± 0.05 26.78and proximal ± 11.71 Adam17KO—HFD tubular 218.63 ± 38.53 Adam17 deletion54.30 ± 8.52mice in theses * (Figure 1A). ± 0.08 wild-type mice 0.42 Obese ± 27.68 * 62.31demonstrated significant glucose intolerance compared to the wild-type group fed an SD after 30, 60, and 120 minHomeostasis 2.2. Glucose post injection. Interestingly, Is Influenced obese by Tubular knockout Adam17 mice presented lesser glucose Deletion intolerance after 120 min post injection as compared to Glucose tolerance was measured, in all groups at 32 weeks obese wild-type of age, bymice. Obese ani- performing an mals with tubular Adam17 deletion showed higher glucose intolerance compared intraperitoneal glucose tolerance test (IPGTT) to evaluate the impact of HFD and proximal to knockout animals fed an SD after 60 min post injection. tubular Adam17 deletion in theses mice (Figure 1A). Obese wild-type mice demonstrated The area significant underintolerance glucose the curve (AUC) comparedvaluetowas increased in the wild-type all obese group fed anmice SD fed an30, after HFD60, compared to control groups (Figure 1B). However, the deletion of Adam17 in and 120 min post injection. Interestingly, obese knockout mice presented lesser glucose the proximal tubule favored intolerance the120 after decrease in AUC min post valueas injection compared compared to to obese wild-type obese mice. wild-type These mice. data Obese suggest the usefulness of our model of HFD-induced obesity in mice to animals with tubular Adam17 deletion showed higher glucose intolerance compared to study metabolic syndrome. knockout animals fed an SD after 60 min post injection. $ $ * * * * * $ $ * Figure 1. Intraperitoneal glucose tolerance tests performed at 32 weeks of age in male mice. (A) Blood glucose levels were Figure 1. Intraperitoneal measured at 0, 15, 30, 60,glucose and 120tolerance min posttests performed glucose bolus at 32 weeks(B) injection. ofArea age inunder male the mice. (A) Blood curve glucose levels was calculated. Datawere are measured as expressed at mean 0, 15, ± 30,SD. 60,Abbreviations: and 120 min post glucose diet; SD, standard bolusHFD, injection. (B)diet; high-fat AreaAdam17WT, under the wild curvetype; wasAdam17KO, calculated.knockout. Data are *expressed as mean p < 0.05 HFD ± SD. vs. SD; $ pAbbreviations: SD, standard diet; HFD, high-fat diet; Adam17WT, wild type; Adam17KO, knock- < 0.05 KO vs. WT. out. * p < 0.05 HFD vs. SD; $ p < 0.05 KO vs. WT. The area under the curve (AUC) value was increased in all obese mice fed an HFD Sodium compared Glucosegroups to control Co-transporter 2 (SGLT2) (Figure 1B). was However, theanalyzed inAdam17 deletion of kidney in samples as the the proximal main tubule promoter favored theofdecrease glucosein reabsorption in the proximal AUC value compared tubule. mice. to obese wild-type We found that These data suggest the usefulness of our model of HFD-induced obesity in mice to study metabolic syndrome. Sodium Glucose Co-transporter 2 (SGLT2) was analyzed in kidney samples as the main promoter of glucose reabsorption in the proximal tubule. We found that hyperglycemia increased SGLT2 expression in obese wild-type mice. When this analysis was performed in obese knockout mice, a significant decrease of SGLT2 expression was found as compared to obese wild-type mice (Figure 2). Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 4 of 16 Int. J. Mol. Sci. 2021, 22, 13093hyperglycemia increased SGLT2 expression in obese wild-type mice. When this analysis 4 of 15 was performed in obese knockout mice, a significant decrease of SGLT2 expression was found as compared to obese wild-type mice (Figure 2). $ * Figure 2. Influence of HFD and proximal tubular Adam17 deletion on SGLT2 protein expression. Quantification of the SGLT2 immunostaining and representative images depicting SGLT2 staining from all experimental groups. 200× magnification, Figure scale 2. Influence of HFD bar 50 µm. Dataand proximal tubular are expressed ± SD. Abbreviations: as meanAdam17 deletion on SGLT2 proteindiet; SD, standard expression. Quantification HFD, high-fat of the wild diet; Adam17WT, SGLT2 type; immunostaining Adam17KO, and representative knockout. * p < 0.05images HFD vs. depicting SD, $ p 40% increase on body weight, higher blood glucose levels, increased albu- altered glucose homeostasis, adiposity, insulin resistance, and hyperlipidemia [16]. At min-to-creatine the kidney level,ratio, andfeeding HFD renal hypertrophy. It is worth leads to albuminuria, mentioning that our glomerulosclerosis, andHFD animals tubular showed just a discrete but significant increase on the ACR ratio without injury [17]. Our animal model adequately demonstrated the key features of type 2 pre- being considered as severe diabetesalbuminuria. including a >40% Regarding increase glucose homeostasis, on body weight, higher obese animalslevels, blood glucose carrying a tubular increased Adam17 deletion showed albumin-to-creatine ratio,lower levels and renal of blood glucose hypertrophy. andmentioning It is worth improved glucose tolerance. that our HFD Thisanimals finding showed wouldjustbe aexplained discrete but by significant two differentincrease on the ACR approaches ratio without previously beingin the proposed considered literature. Oneaswould severebe albuminuria. the influence Regarding glucose of high blood homeostasis, glucose levels obese animals in inducing car- hyperacti- rying a tubular Adam17 deletion showed lower levels of blood vation of the sympathetic nervous system and also promoting ADAM17 expression [18]. glucose and improved glucose tolerance. This finding would be explained by two different approaches previously Matthews et al. hypothesized that an increase in ADAM17 induces renal sympathetic proposed in the literature. One would be the influence of high blood glucose levels in nervous system activity and in turn induces SGLT2 (Sodium Glucose Cotransporter 2) inducing hyperactivation of the sympathetic nervous system and also promoting ADAM17 expression, which promotes glucose reabsorption and hyperglycemia [18]. In this line, our study demonstrated that Adam17 deletion on proximal tubular cells prevents increased blood glucose levels and glucose intolerance to a lesser extent. These results suggested that Adam17 deletion in proximal tubular cells may decrease SGLT2 activity by hindering Int. J. Mol. Sci. 2021, 22, 13093 9 of 15 expression [18]. Matthews et al. hypothesized that an increase in ADAM17 induces renal sympathetic nervous system activity and in turn induces SGLT2 (Sodium Glucose Cotrans- porter 2) expression, which promotes glucose reabsorption and hyperglycemia [18]. In this line, our study demonstrated that Adam17 deletion on proximal tubular cells prevents increased blood glucose levels and glucose intolerance to a lesser extent. These results suggested that Adam17 deletion in proximal tubular cells may decrease SGLT2 activity by hindering glucose reabsorption that favors its excretion in urine. A second approach would be the reduction of systemic insulin resistance by the decrease in chronic inflammation due to the Adam17 deletion. As previously hypothesized in the adipose tissue, macrophages play an active role in morbid obesity, and macrophage-related inflammatory activities may contribute to the pathogenesis of obesity-induced insulin resistance [4]. Therefore, more studies focused on ADAM17; SGLT2 or chronic inflammation interaction should be performed in more detail in the context of hyperglycemia. Marked renal structural changes were seen in obese mice in comparison with the kidneys of lean control animals including global glomerulosclerosis and tubular injury. Regarding glomeruli, previous studies reported the presence of glomerular and mesangial matrix expansion in high-fat diet-fed mice [9,19,20]. Our histological analyses revealed glomerular alterations in obese mice due to an increase in the glomerular tuft area and mesangial expansion. Instead, glomerular hypertrophy and mesangial matrix expansion induced by high blood glucose levels and obesity condition were reduced in Adam17 knockout mice. These results suggested that the tissue-specific deletion of Adam17 at proximal tubular cells protected glomeruli from the deleterious effects of a high-fat diet. In this line, Bruneval et al. have described macrophage infiltration in the glomeruli of ApoE knockout mice, which is a model of hyperlipidemia. They presume that macrophage infiltration might be mediated by the local activation of glomerular endothelial cells. These infiltrated macrophages could transform into foam cells, which may contribute to the development of the mesangial expansion observed in ApoE-null mice [21]. In concordance, Adam17 deletion in proximal tubular cells may slow down mesangial matrix expansion by decreasing glomerular inflammation in obese mice. Previous studies have demonstrated podocyte loss in HFD-fed mice [22,23]. In the same line, we observed a decrease in podocyte number in the glomeruli of all obese mice. Interestingly, Guo et al. described TNF-α as a key mediator of high-glucose-activated macrophages to induce podocyte apoptosis [24]. This could explain why obese mice with higher blood glucose levels have a decreased number of podocytes. Higher blood glucose levels and hyperlipidemia would lead to the activation of Adam17 that, in turn, stimulates TNF-α shedding and activation. Blocking renal Adam17 expression at a proximal tubular level decreased podocyte loss. Probably, this genetic modification might have induced a tubular–glomerular feedback recovery that leads to podocyte protection by blocking TNF-α signaling in obese mice. The decrease in glomerular hypertrophy observed in the Adam17-obese KO mice may reflect the restauration of the tubular–glomerular feedback. In our study, macrophage/monocyte infiltration was observed in the glomeruli of obese mice. F4/80 positive cells were increased in the glomeruli of HFD-fed mice as compared with SD mice. In contrast, no differences were observed when analyzing tubu- lointerstitial F4/80 immunostaining. These results are in concordance with previous studies that showed glomerular inflammation caused by macrophage infiltration without changes in the tubulointerstitial compartment [25,26]. Adam17 deletion protected obese mice from glomerular macrophage infiltration, suggesting that the TNF-α signaling pathway is atten- uated in Adam17 knockout proximal tubular cells. EGFR hyperactivation by hyperglycemia has also been linked to oxidative stress and fibrosis [27]. More concretely, EGFR-dependent ERK or MAPK signaling mediates TGF-β expression in renal fibrosis, which favors diabetic nephropathy progression through en- hancing the synthesis of collagen, fibronectin, and laminin [27–29]. To further describe the effect of Adam17 deletion on obese mice, we analyzed collagen type I and III depositions in different renal compartments. No differences were observed between groups regard- Int. J. Mol. Sci. 2021, 22, 13093 10 of 15 ing interstitial collagen depositions. In contrast, when focusing at the glomerular level, higher collagen depositions were observed in obese mice, as previously described [27,30]. Interestingly, Fang Q et al. have demonstrated that EGFR inhibition was able to decrease renal fibrosis in HFD-fed mice [27]. In the same line, our results showed that Adam17 deletion was able to protect the glomeruli of obese mice from collagen depositions, prob- ably by decreasing EGFR signaling. It is worth mentioning that at the gene expression level, collagen type IV α1 was found decreased in obese wild-type mice. This type of collagen participates in the maintenance of the tissue structure [31]. The deletion of Adam17 returns the expression to basal levels, contributing to reducing the structural changes in the pre-diabetic kidney. Galectin-3 has been also linked to the development of renal fibrosis in animal models by regulating myofibroblast activation [32,33]. Elevated serum levels of Galectin-3 have been associated with a higher risk of incident CKD and renal dysfunction, suggesting that Galectin-3 can predict renal damage [34]. Kikuchi et al. demonstrated that in normal human kidney, Galectin-3 was detected in the distal tubules but not in the glomeruli. In contrast, Galectine-3-positive cells appear in the glomeruli of patients with diabetic nephropathy. Moreover, they observed that the ratio of Galectin-3-positive cells to the total number of interstitial macrophages was significantly increased during diabetic nephropathy [35]. In agreement with these observations, our SD mice presented a lower cortical expression of Galectin-3 without any positive staining in the glomeruli. In contrast, in obese mice, most glomeruli showed Galectin-3 positive cells. As macrophages have been identified as the major sources of Galectin-3 [36,37], we surmise that the higher macrophage infiltration observed in the glomeruli of the obese mice induced the increased production of Galectin-3 inside the glomerulus. These findings suggest that the Galectin-3 staining pattern could be affected by the HFD-induced glucose alterations. Interestingly, Adam17 deletion on proximal tubular cells tended to decrease Galectin-3-positive staining in the glomeruli probably by decreasing glomerular inflammation. Oxidative stress is a key pathogenic factor in diabetes- and obesity-related nephropa- thy that leads to the development and progression of kidney injury [38,39]. Both mito- chondria and NADPH oxidases (Nox) are accepted as major sources of ROS in diabetic nephropathy and chronic kidney disease. Thus, mitochondria-derived oxidative stress has been associated to kidney pro-inflammatory and structural changes in response to lipid overload in obese mice [40]. Moreover, Nox4 is the most abundantly expressed Nox isoform in the kidney, and it has been found to be upregulated and linked to the stimulation of TFG-β and matrix genes, leading to the activation of pro-fibrotic processes associated to kidney fibrosis in diabetic nephropathy [41]. Previous studies have also reported in- creased Nox4 gene expression in obese animals [42,43]. In concordance, our results showed increased Nox4gene expression in our HFD-fed mice model. Interestingly, this increase in Nox4, induced by the high-fat diet, was not observed in Adam17 knockout mice in the proximal tubular cells. Our results are in line with the previous studies of Wang et al., which demonstrated that TNF-α deletion decreased Nox4gene expression in the kidney cortex of obese mice [44]. Our results suggest an important role of inflammatory pathways mediated by ADAM17 in the proximal tubular cells. We have demonstrated how this protein impacts on glomeruli and in the tubule. The description of the influence of renal tubular cells modifications in other renal structures highlights the importance of the renal proximal tubular cells in maintaining the tubuloglomerular balance. Concretely, Adam17 deletion in proximal tubular cells ameliorates glucose homeostasis concomitant with the reduction of SGLT2 and protects against glomerular alterations including glomerular hypertrophy, mesan- gial expansion, podocyte loss, macrophage infiltration, and fibrosis in an HFD-induced pre-diabetic and obese mice model. Our results abrogate for a partial blocking of the inflammatory and fibrotic processes induced by ADAM17-related pathways as adjuvant treatment for renal pathologies associated to obesity and high glucose levels. Therefore, Int. J. Mol. Sci. 2021, 22, 13093 11 of 15 the blockage of ADAM17 could be a potential therapeutic target for patients with obesity and/or hyperglycemia. 4. Materials and Methods 4.1. Animal Experiments Experiments were performed on wild-type and proximal-tubular Adam17KO male mice on C57BL/6 background. Mice were housed in ventilated cages with full access to chow and water. Adam17 was conditionally deleted in renal proximal tubular cells as previously described by our group [15]. Briefly, the generation of specific proximal tubular knockout mice occurred spontaneously by crossing Adam17flox/flox mice (kindly provided by Dr. Raines, Washington University) [45] and spontaneous phosphoenolpyruvate car- boxykinase (Pepck)-CreER mice (kindly provided by Dr. Haase, Vanderbilt University) [46]. The Pepck-CreER transgene contains a mutated version of the Pepck promoter, which reduces Pepck expression in the liver by 60% and increases Pepck expression in the kidney by 10-fold [47]. Adam17flox/flox mice presented two loxP sites surrounding exon 5 of the Adam17 gene [45]. Exon 5 was selected for deletion as it encodes for the carboxyl-terminus of the prodomain, upstream of the mature protein, and excision of the sequence results in a frame shift [45]. To induce obesity, at 10 weeks of age, mice were divided randomly into two groups according to diet. Wild-type (Adam17-WT) and knockout (Adam17-KO) mice were fed a high-fat diet (HFD, 60.3% fat; TD.06414, Envigo, Indianapolis, IN, USA) or standard rodent chow (SD) for controls (7.4% fat; 801151, SDS) during 22 weeks (Supplementary Figure S1). Body weight and fasting blood glucose (BG) from the caudal vein were measured every two weeks until the end of the follow-up. Mice were considered diabetic when BG > 250 mg/dL. At the end of the follow-up, mice were sacrificed by terminal surgery as previously described [48]. Blood was extracted by cardiac puncture, and serum was obtained by centrifugation at 6000× g for 10 min. Mice were perfused with cold PBS prior to kidneys removal and weighting. Half of the right kidney was maintained in 10% formalin solution for paraffin embedding. The remaining tissue was snap frozen on liquid nitrogen and kept at −80 ◦ C for further analyses. 4.2. Glucose Tolerance Test An intraperitoneal glucose tolerance test (IPGTT) was performed 3 days before the end of the study. Mice were fasted for 6 h prior to the test as previously described [49]. Briefly, 2 g/Kg of D-glucose (Sigma-Aldrich, St. Louis, MO, USA) were administrated intraperitoneally, and blood glucose levels were recorded after 15 min, 30 min, 60 min, and 120 min of bolus injection with an Accu-Chek Compact glucometer (Roche, Basel, Switzerland). 4.3. Urine Albumin Creatinine Ratio The albumin-to-creatinine (ACR) ratio was determined on morning spot urine collec- tions obtained on the last week of the follow-up. Urinary albumin levels were measured by ELISA kit (Albuwell M, Exocell, Philadelphia, PA, USA). Creatinine levels were measured by colorimetric assay (Creatinine Companion, Exocell). The albumin-to-creatinine ratio was calculated and expressed as µg Alb/mg Crea [50]. 4.4. Immunohistochemistry on Paraffined-Embedded Tissue Paraffin-embedded tissues were cut into 3 µm sections, deparaffined in xylene, and rehydrated through graded alcohols. Sections were stained with periodic acid of Schiff (PAS) for glomerular area and mesangial matrix expansion measurements as previously reported [51]. Then, 20 microphotographs of glomeruli were taken at ×400 magnification for each animal. Image J software was used to analyze glomerular areas. Immunohistochemistry for podocyte marker Wilms Tumor 1 (WT-1), Galectin-3 (Gal- 3), macrophage marker F4/8, and SGLT2 was also performed in sections of paraffin- Int. J. Mol. Sci. 2021, 22, 13093 12 of 15 embedded tissue. Antigen retrieval was carried out with 0.01 M sodium citrate buffer pH6 by heating in a pressure cooker. Endogenous peroxidase was blocked by 3% H2 O2 in TBS1X incubation for 15 min. Non-specific interactions blocking was done by 1% BSA and 3% goat serum for 1 h. Then, sections were incubated with anti-WT-1 antibody (1:1000; sc192, Santa Cruz Biotechnology, Dallas, TX, USA), anti-Galectin-3 antibody (1:1000; 126701, Biolegend, San Diego, CA, USA), anti-F4/80 antibody (1:500; 400501, Biolegend, San Diego, CA, USA), or anti-SGLT2 antibody (1:200; 24654-1-AP, Proteintech, Manchester, UK) at 4 ◦ C overnight. After washing, the slides were incubated with HRP-conjugated anti-rabbit IgG, anti-mouse IgG, or anti-rat IgG during 1 h at room temperature. Binding of the antibodies was detected by oxidation of DAB using the Liquid DAB + Substrate Chromogen System (Dako, Santa Clara, CA, USA). Samples were counterstained with hematoxylin and dehydrated through graded alcohols and preserved with DPX mounting media (Sigma). Then, 20 microphotographs of glomeruli stained with anti-WT-1 were taken at ×400 magnification. Representative microphotographs of renal cortex stained with anti-SGLT2, anti-Gal-3, or anti-F4/80 were taken at ×200 magnification. Picrosirius red staining, as a marker of collagen type I and type III, was performed on 4.5 µm sections of paraffin-embedded kidneys as previously described [52]. Representative images were taken at ×400 magnifications. 4.5. Western Blot Kidney cortical tissue was prepared for immunoblot analysis with antibodies against phosphorylated and total Drp1. Kidney cortex samples were homogenized in extraction buffer containing 50 mM HEPES, pH7.4, 150 mM NaCl, 0.5% Triton X-100, 0.025 mM ZnCl2, 0.1 mM Pefabloc SC Plus (Roche, Basel, Switzerland), EDTA-free protease inhibitor cocktail tablet (Roche, Basel, Switzerland), and phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was determined using the Micro BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA). Western blot was performed by separating 15 µg of total protein in 7% SDS-polyacrylamide gels and transferring into PVDF membranes (Immobilon-P Millipore). Membranes were incubated in skimmed milk blocking solution (5%) for 1 h and incubated overnight at 4 ◦ C with anti-pDrp1 (Ser616) antibody (1:1000; 4494S, Cell Signaling, Danvers, MA, USA) in 2.5% BSA, anti-Drp1 antibody (5391T, Cell Signaling; 1:1000) in 2.5% BSA, and MCP-1 antibody (1:500; TA336914, Origen, Herford, Germany). HRP-conjugated anti-rabbit IgG antibody and HRP-conjugated anti-mouse IgG antibody were used as secondary antibodies. β-Actin antibody (1:20,000; BS1003, Bioworld, Dublin, Ireland) was used as loading control. Proteins were detected in films (AGFA CURIX) after 3 min incubation with Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA). Protein bands were quantified by densitometry with the ImageJ software. 4.6. Gene Expression Renal cortex RNA was isolated from frozen tissue using the Tripure Isolation Rea-gent (Sigma-Aldrich, St. Louis, MO, USA), as previously reported [53]. First, 1.5 µg of total RNA were retrotranscribed using the High-Capacity cDNA RT Kit (ThermoFisher Scientific, Waltham, MA, USA). Gene expressions for tumor necrosis factor alpha (TNF-α), type IV α1 Collagen, and NADPH Oxidase 4 (Nox4) were determined by Real-Time PCR using LightCycler® 480 SYBR Green I Master Mix (Roche, Basel, Switzerland). Glyceraldehyde-3- phosphate dehydrogenase (Gapdh) was used as a housekeeping gene. Primer sequences were synthesized by Sigma and described in Supplementary Table S1. 4.7. Statistical Analyses Statistical analyses between groups were performed by one-way ANOVA test (SPSS 22.0 software). Non-parametric Kruskal–Wallis tests were performed between groups. Non-parametric Mann–Whitney tests were used for group-to-group comparisons. Data were expressed as mean ± SD. Significance was defined as p < 0.05. Int. J. Mol. Sci. 2021, 22, 13093 13 of 15 Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/ijms222313093/s1. Author Contributions: Conceptualization, M.R. and M.J.S.; methodology, V.P., S.V., J.J., D.B.; vali- dation, M.R., C.B. and J.G.; formal analysis, V.P., S.V., J.J., M.R., E.M., E.R., A.O., L.S.; investigation, V.P., M.R.; data curation, V.P., S.V., J.J., M.R.; writing—original draft preparation, V.P., M.R.; writing— review and editing, all authors; supervision, M.R.; funding acquisition, J.P., C.B., M.C. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by ISCIIII-FEDER grant numbers PI16/00620 and PI17/00257; ISCIII-RETICS REDinREN RD16/0009/0013, and ISCIII-RICORS RD21/0005. C.B. is also funded by the Catalan Health Department (Generalitat de Catalunya) contract PERIS STL008/18/00018 to develop clinical and epidemiological studies mainly focused on diabetes and its associations with new biomarkers. V.P. is a research fellow of ISCIII-FSE project FI17/00025. Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Animal Experimentation of the Barcelona Biomedical Research Park and the Catalan Government (DMAH no. 9302; 2017.07.04). Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Acknowledgments: The authors would like to thank Daniel Camacho, Ainhoa Garcia, and Júlia Terzulli for their technical assistance. Conflicts of Interest: The authors declare no conflict of interest. References 1. Kovesdy, C.P.; Furth, S.L.; Zoccali, C. Obesity and kidney disease: Hidden consequences of the epidemic. J. Bras. Nefrol. 2017, 39, 1–10. [CrossRef] 2. Kassi, E.; Pervanidou, P.; Kaltsas, G.; Chrousos, G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011, 9, 1–13. [CrossRef] [PubMed] 3. Shoelson, S.E.; Herrero, L.; Naaz, A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology 2007, 132, 2169–2180. [CrossRef] [PubMed] 4. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 2003, 112, 1821–1830. [CrossRef] 5. Blobel, C.P. ADAMs: Key components in egfr signalling and development. Nat. Rev. Mol. Cell Biol. 2005, 6, 32–43. [CrossRef] [PubMed] 6. Edwards, D.R.; Handsley, M.M.; Pennington, C.J. The ADAM metalloproteinases. Mol. Asp. Med. 2009, 29, 258–289. [CrossRef] 7. Göoz, M. ADAM Proteases as Novel Therapeutic Targets in Chronic Kidney Disease. In Chronic Kidney Disease; Göoz, M., Ed.; InTech: Rijeka, Croatia, 2012; pp. 3–12. 8. Menghini, R.; Fiorentino, L.; Casagrande, V.; Lauro, R.; Federici, M. The role of ADAM17 in metabolic inflammation. Atherosclerosis 2013, 228, 12–17. [CrossRef] 9. Deji, N.; Kume, S.; Araki, S.I.; Soumura, M.; Sugimoto, T.; Isshiki, K.; Chin-Kanasaki, M.; Sakaguchi, M.; Koya, D.; Haneda, M.; et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am. J. Physiol. Ren. Physiol. 2009, 296, 118–126. [CrossRef] 10. Serino, M.; Menghini, R.; Fiorentino, L.; Amoruso, R.; Mauriello, A.; Lauro, D.; Sbraccia, P.; Hribal, M.L.; Lauro, R.; Federici, M. Mice heterozygous for tumor necrosis factor-α converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007, 56, 2541–2546. [CrossRef] [PubMed] 11. Kaneko, H.; Anzai, T.; Horiuchi, K.; Morimoto, K.; Anzai, A.; Nagai, T.; Sugano, Y.; Maekawa, Y.; Itoh, H.; Yoshikawa, T.; et al. Tumor necrosis factor-α converting enzyme inactivation ameliorates high-fat diet-induced insulin resistance and altered energy homeostasis. Circ. J. 2011, 75, 2482–2490. [CrossRef] 12. Melenhorst, W.B.; Visser, L.; Timmer, A.; van den Heuvel, M.C.; Stegeman, C.A.; van Goor, H. ADAM17 upregulation in human renal disease: A role in modulating TGF-α availability? Am. J. Physiol. Physiol. 2009, 297, 781–790. [CrossRef] 13. Yao, M.; Li, L.; Huang, M.; Tan, Y.; Shang, Y.; Meng, X.; Pang, Y.; Xu, H.; Zhao, X.; Lei, W.; et al. Sanye Tablet Ameliorates Insulin Resistance and Dysregulated Lipid Metabolism in High-Fat Diet-Induced Obese Mice. Front. Pharmacol. 2021, 12, 2606. [CrossRef] [PubMed] 14. Palau, V.; Pascual, J.; Soler, M.J.; Riera, M. Role of ADAM17 in kidney disease. Am. J. Physiol. Physiol. 2019, 317, 333–342. [CrossRef] Int. J. Mol. Sci. 2021, 22, 13093 14 of 15 15. Palau, V.; Nugraha, B.; Benito, D.; Pascual, J.; Emmert, M.Y.; Hoerstrup, S.P.; Riera, M.; Soler, M.J. Both specific endothelial and proximal tubular ADAM17 deletion protect against diabetic nephropathy. Int. J. Mol. Sci. 2021, 22, 5520. [CrossRef] [PubMed] 16. He, M.Q.; Wang, J.Y.; Wang, Y.; Sui, J.; Zhang, M.; Ding, X.; Zhao, Y.; Chen, Z.Y.; Ren, X.X.; Shi, B.Y. High-fat diet-induced adipose tissue expansion occurs prior to insulin resistance in C57BL/6J mice. Chronic Dis. Transl. Med. 2020, 6, 198–207. [CrossRef] 17. Sun, Y.; Ge, X.; Li, X.; He, J.; Wei, X.; Du, J.; Sun, J.; Li, X.; Xun, Z.; Liu, W.; et al. High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction. Cell Death Dis. 2020, 11, 1–14. [CrossRef] [PubMed] 18. Matthews, J.; Villescas, S.; Herat, L.; Schlaich, M.; Matthews, V. Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes. Biosci. Rep. 2021, 41, BSR20210029. [CrossRef] 19. Declèves, A.E.; Mathew, A.V.; Cunard, R.; Sharma, K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol. 2011, 22, 1846–1855. [CrossRef] [PubMed] 20. Wei, P.; Lane, P.H.; Lane, J.T.; Padanilam, B.J.; Sansom, S.C. Glomerular structural and functional changes in a high-fat diet mouse model of early-stage Type 2 diabetes. Diabetologia 2004, 47, 1541–1549. [CrossRef] 21. Bruneval, P.; Bariéty, J.; Bélair, M.F.; Mandet, C.; Heudes, D.; Nicoletti, A. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol. Dial. Transplant. 2002, 17, 2099–2107. [CrossRef] 22. Shevalye, H.; Lupachyk, S.; Watcho, P.; Stavniichuk, R.; Khazim, K.; Abboud, H.E.; Obrosova, I.G. Prediabetic nephropathy as an early consequence of the high-calorie/high- fat diet: Relation to oxidative stress. Endocrinology 2012, 153, 1152–1161. [CrossRef] 23. Boini, K.M.; Xia, M.; Abais, J.M.; Li, G.; Pitzer, A.L.; Gehr, T.W.B.; Zhang, Y.; Li, P.L. Activation of inflammasomes in podocyte injury of mice on the high fat diet: Effects of ASC gene deletion and silencing. Biochim. Biophys. Acta Mol. Cell Res. 2014, 1843, 836–845. [CrossRef] [PubMed] 24. Guo, Y.; Song, Z.; Zhou, M.; Yang, Y.; Zhao, Y.; Liu, B.; Zhang, X. Infiltrating macrophages in diabetic nephropathy promote podocytes apoptosis via TNF-α-ROS-p38MAPK pathway. Oncotarget 2017, 8, 53276–53287. [CrossRef] [PubMed] 25. Lee, S.J.; Kang, J.S.; Kim, H.M.; Lee, E.S.; Lee, J.H.; Chung, C.H.; Lee, E.Y. CCR2 knockout ameliorates obesity-induced kidney injury through inhibiting oxidative stress and ER stress. PLoS ONE 2019, 14, e0222352. [CrossRef] [PubMed] 26. Kim, D.H.; Chun, S.Y.; Lee, E.H.; Kim, B.; Yoon, B.H.; Gil, H.; Han, M.H.; Ha, Y.S.; Lee, J.N.; Kwon, T.G.; et al. IL-10 Deficiency Aggravates Renal Inflammation, Fibrosis and Functional Failure in High-Fat Dieted Obese Mice. Tissue Eng. Regen. Med. 2021, 18, 399–410. [CrossRef] 27. Fang, Q.; Zou, C.; Zhong, P.; Lin, F.; Li, W.; Wang, L.; Zhang, Y.; Zheng, C.; Wang, Y.; Li, X.; et al. EGFR mediates hyperlipidemia- induced renal injury via regulating inflammation and oxidative stress: The detrimental role and mechanism of EGFR activation. Oncotarget 2016, 7, 24361–24373. [CrossRef] 28. McLennan, S.V.; Fisher, E.; Martell, S.Y.; Death, A.K.; Williams, P.F.; Lyons, J.G.; Yue, D.K. Effects of glucose on matrix metallo- proteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy. Kidney Int. Suppl. 2000, 77, 81–87. [CrossRef] 29. Ayo, S.H.; Radnik, R.A.; Garoni, J.A.; Glass, W.F.; Kreisberg, J.I. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am. J. Pathol. 1990, 136, 1339–1348. 30. Xu, H.; Ma, Z.; Lu, S.; Li, R.; Lyu, L.; Ding, L.; Lu, Q. Renal resistive index as a novel indicator for renal complications in high-fat diet-fed mice. Kidney Blood Press. Res. 2017, 42, 1128–1140. [CrossRef] 31. Zhu, D.; Kim, Y.; Steffes, M.W.; Groppoli, T.J.; Butkowski, R.J.; Mauer, S.M. Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry. Kidney Int. 1994, 45, 425–433. [CrossRef] 32. Chen, S.C.; Kuo, P.L. The role of galectin-3 in the kidneys. Int. J. Mol. Sci. 2016, 17, 565. [CrossRef] [PubMed] 33. Henderson, N.C.; Mackinnon, A.C.; Farnworth, S.L.; Kipari, T.; Haslett, C.; Iredale, J.P.; Liu, F.T.; Hughes, J.; Sethi, T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 2008, 172, 288–298. [CrossRef] 34. Hara, A.; Niwa, M.; Noguchi, K.; Kanayama, T.; Niwa, A.; Matsuo, M.; Hatano, Y.; Tomita, H. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules 2020, 10, 389. [CrossRef] 35. Kikuchi, Y.; Kobayashi, S.; Hemmi, N.; Ikee, R.; Hyodo, N.; Saigusa, T.; Namikoshi, T.; Yamada, M.; Suzuki, S.; Miura, S. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol. Dial. Transplant. 2004, 19, 602–607. [CrossRef] 36. Farhad, M.; Rolig, A.S.; Redmond, W.L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology 2018, 7, e1434467. [CrossRef] 37. Okamura, D.M.; Pasichnyk, K.; Lopez-Guisa, J.M.; Collins, S.; Hsu, D.K.; Liu, F.T.; Eddy, A.A. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am. J. Physiol. Ren. Physiol. 2011, 300, F245–F253. [CrossRef] [PubMed] 38. Forbes, J.M.; Coughlan, M.T.; Cooper, M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57, 1446–1454. [CrossRef] 39. Sharma, K. Obesity and Diabetic Kidney Disease: Role of Oxidant Stress and Redox Balance. Antioxid. Redox Signal. 2016, 25, 208–216. [CrossRef] 40. Ruggiero, C.; Ehrenshaft, M.; Cleland, E.; Stadler, K. High-fat diet induces an initial adaptation of mitochondrial bioenergetics in the kidney despite evident oxidative stress and mitochondrial ROS production. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E1047–E1058. [CrossRef] [PubMed] Int. J. Mol. Sci. 2021, 22, 13093 15 of 15 41. Muñoz, M.; López-Oliva, M.E.; Rodríguez, C.; Martínez, M.P.; Sáenz-Medina, J.; Sánchez, A.; Climent, B.; Benedito, S.; García- Sacristán, A.; Rivera, L.; et al. Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity. Redox Biol. 2020, 28, 101330. [CrossRef] 42. Zhang, S.Q.; Sun, Y.T.; Xu, T.H.; Zhang, X.F.; Liu, Y.Z.; Ma, J.F.; Wang, L.N.; Yao, L. Protective effect of metformin on renal injury of C57BL/6J mouse treated with high fat diet. Pharmazie 2014, 69, 904–908. [CrossRef] 43. Jiang, F.; Lim, H.K.; Morris, M.J.; Prior, L.; Velkoska, E.; Wu, X.; Dusting, G.J. Systemic upregulation of NADPH oxidase in diet-induced obesity in rats. Redox Rep. 2011, 16, 223–229. [CrossRef] 44. Gai, Z.; Kullak-Ublick, G.A. TNF-α Deficiency Prevents Renal Inflammation and Oxidative Stress in Obese Mice. Kidney Blood Press. Res. 2017, 42, 416–427. [CrossRef] 45. Wilson, C.L.; Gough, P.J.; Chang, C.A.; Chan, C.K.; Frey, J.M.; Liu, Y.; Braun, K.R.; Chin, M.T.; Wight, T.N.; Raines, E.W. Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults. Mech. Dev. 2013, 130, 272–289. [CrossRef] 46. Rankin, E.B.; Tomaszewski, J.E.; Haase, V.H. Renal cyst development in mice with conditional inactivation of the von Hippel- Lindau tumor suppressor. Cancer Res. 2006, 66, 2576–2583. [CrossRef] [PubMed] 47. Patel, Y.M.; Yun, J.S.; Liu, J.; McGrane, M.M.; Hanson, R.W. An analysis of regulatory elements in the phosphoenolpyruvate carboxykinase (GTP) gene which are responsible for its tissue-specific expression and metabolic control in transgenic mice. J. Biol. Chem. 1994, 269, 5619–5628. [CrossRef] 48. Clotet, S.; Soler, M.J.; Rebull, M.; Gimeno, J.; Gurley, S.B.; Pascual, J.; Riera, M. Gonadectomy prevents the increase in blood pressure and glomerular injury in angiotensin-converting enzyme 2 knockout diabetic male mice. Effects on renin-angiotensin system. J. Hypertens. 2016, 34, 1752–1765. [CrossRef] [PubMed] 49. Roca-Ho, H.; Palau, V.; Gimeno, J.; Pascual, J.; Soler, M.J.; Riera, M. Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice. Lab. Investig. 2020, 100, 1169–1183. [CrossRef] [PubMed] 50. Riera, M.; Anguiano, L.; Clotet, S.; Roca-Ho, H.; Rebull, M.; Pascual, J.; Soler, M.J. Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. Am. J. Physiol. Physiol. 2016, 310, 534–546. [CrossRef] 51. Riera, M.; Márquez, E.; Clotet, S.; Gimeno, J.; Roca-Ho, H.; Lloreta, J.; Juanpere, N.; Batlle, D.; Pascual, J.; Soler, M.J. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PLoS ONE 2014, 9, e84683. [CrossRef] 52. Junqueira, L.C.U.; Bignolas, G.; Brentani, R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 1979, 11, 447–455. [CrossRef] [PubMed] 53. Clotet-Freixas, S.; Soler, M.J.; Palau, V.; Anguiano, L.; Gimeno, J.; Konvalinka, A.; Pascual, J.; Riera, M. Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy. Lab. Investig. 2018, 98, 1237–1249. [CrossRef] [PubMed]